›
^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersTEST:Devyser HBOC NGS
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
DevyserType:
CE Marked
Related tests:
The Devyser HBOC gene panel has been developed with an integrative approach towards the varying literature and expert recommendations for follow-up after negative BRCA testing. It can also be employed as a first-line protocol simultaneously with BRCA1 and BRCA2, extending the screening by an additional 12 genes. Its purpose is to pinpoint mutations in genes with a recognised connection to the development of breast and ovarian cancers.
Cancer:
Breast Cancer, Ovarian Cancer
Gene:
ATM (ATM serine/threonine kinase), BARD1 (BRCA1 Associated RING Domain 1), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CDH1 (Cadherin 1)
See More ...
ATM (ATM serine/threonine kinase), BARD1 (BRCA1 Associated RING Domain 1), BRCA1 (Breast cancer 1, early onset), BRCA2 (Breast cancer 2, early onset), BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1), CDH1 (Cadherin 1), CHEK2 (Checkpoint kinase 2), NBN (Nibrin Nijmegen Breakage Syndrome 1 (Nibrin)), PALB2 (Partner and localizer of BRCA2), PTEN (Phosphatase and tensin homolog), RAD51C (RAD51 paralog C), RAD51D (RAD51 paralog D), STK11 (Serine/threonine kinase 11), TP53 (Tumor protein P53)
Method:
Next-Generation Sequencing (NGS)
Approvals
Date
Cancer
Gene
Biomarker
Drug
Approved by
